Opin vísindi

Fletta eftir höfundi "Grøn, Kathrine Lederballe"

Fletta eftir höfundi "Grøn, Kathrine Lederballe"

Röðun: Raða: Niðurstöður:

  • Icon
    Active conventional treatment and three different biological treatments in early rheumatoid arthritis : Phase IV investigator initiated, randomised, observer blinded clinical trial 
    Hetland, Merete Lund; Haavardsholm, Espen A.; Rudin, Anna; Nordström, Dan; Nurmohamed, Michael; Gudbjornsson, Bjorn; Lampa, Jon; Hørslev-Petersen, Kim; Uhlig, Till; Grondal, Gerdur; Østergaard, Mikkel; Heiberg, Marte S.; Twisk, Jos; Lend, Kristina; Krabbe, Simon; Hyldstrup, Lise Hejl; Lindqvist, Joakim; Hultgård Ekwall, Anna Karin; Grøn, Kathrine Lederballe; Kapetanovic, Meliha; Faustini, Francesca; Tuompo, Riitta; Lorenzen, Tove; Cagnotto, Giovanni; Baecklund, Eva; Hendricks, Oliver; Vedder, Daisy; Sokka-Isler, Tuulikki; Husmark, Tomas; Ljoså, Maud Kristine Aga; Brodin, Eli; Ellingsen, Torkell; Söderbergh, Annika; Rizk, Milad; Olsson, Åsa Reckner; Larsson, Per; Uhrenholt, Line; Just, Søren Andreas; Stevens, David John; Laurberg, Trine Bay; Bakland, Gunnstein; Olsen, Inge C.; Van Vollenhoven, Ronald (2020-12-02)
    AbstractObjective To evaluate and compare benefits and harms of three biological treatments with different modes of action versus active conventional treatment in patients with early rheumatoid arthritis. Design Investigator initiated, randomised, open ...
  • Icon
    Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs : results from four Nordic countries 
    Delcoigne, Benedicte; Ljung, Lotta; Provan, Sella A; Glintborg, Bente; Hetland, Merete Lund; Grøn, Kathrine Lederballe; Peltomaa, Ritva; Relas, Heikki; Turesson, Carl; Guðbjörnsson, Björn; Michelsen, Brigitte; Askling, Johan (2022-03-22)
    OBJECTIVES: To compare the 1-year, 2-year and 5-year incidences of acute coronary syndrome (ACS) in patients with rheumatoid arthritis (RA) starting any of the biologic disease-modifying antirheumatic drugs (bDMARDs) currently available in clinical ...